Contact this trialFirst, we need to learn more about you.
PI3K Inhibitor
Dietary Changes + Canagliflozin for Metastatic Breast Cancer
Recruiting1 awardPhase 2
Columbus, Ohio
This trial will study whether a low-carb or ketogenic diet, or the drug canagliflozin, can help prevent high blood sugar and improve the effectiveness of cancer therapy in people with metastatic PIK3CA-mutant breast cancer who are receiving standard treatment with alpelisib and fulvestrant.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.